$CRAI

CRAI Jumps 20% in 3 Months as Demand Broadens Across Key Practices

Charles River Associates (CRAI) shares rose about 20% over three months. In Q2, revenue grew 12.8% to $210.8 million, with gains across most practices. Management raised fiscal 2026 constant-currency revenue guidance to $805-$820 million and kept a 12%-13% non-GAAP EBITDA margin outlook, while higher costs and working-capital pressure affect cash conversion.

Original reporting
Published Aug 11, 2026, 1:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 3:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CRAI Jumps 20% in 3 Months as Demand Broadens Across Key Practices — source image
Decision brief

The 30-second read

$CRAIBullishMed
01

Why it matters

Raised revenue guidance and broad practice growth improve the operating case, but higher talent-related costs and weaker cash conversion increase the risk that earnings quality lags revenue momentum.

02

Market read

A guidance increase plus broad-based practice growth is a near-term positive catalyst, but cash conversion and margin pressure are the key swing factors for traders.

03

What to watch

Receivables elevation and revolver borrowings are emphasized; traders may want to monitor whether lead-flow converts into cash faster than margins deteriorate.

Relevance 6/10Novelty 6/10Timing: post-guidance update, investors reassess near-term margin and cash-conversion outlook

Background

The article frames CRAI’s recent share performance alongside Q2 operating momentum, pipeline indicators, and an updated fiscal 2026 guidance range.

Company-level read

Ticker impact

$CRAIBullishMedium confidence
Context

CRA International raised fiscal 2026 constant-currency revenue guidance to $805-$820 million after Q2 revenue grew 12.8% to $210.8 million.

Expected impact

Bias modestly positive, with follow-through dependent on collections and margin stabilization.

Evidence & confidence

The article provides specific Q2 growth, practice breadth, and guidance numbers, alongside concrete cost and cash-conversion headwinds (DSO 113 days, revolver borrowings, operating cash use).

Market effects

Signals continued demand breadth in advisory/consulting practices, but highlights cash-conversion sensitivity that can matter for peers’ margin quality.

No explicit regional demand or macro linkage beyond general consulting backdrop.

Limited; the disclosure is company-specific with no stated cross-border catalyst.

Counterpoint

The stock’s 20% run may already price in demand strength, while the working-capital and margin deterioration could cap upside if collections lag.

Key entities

  • CRA International, Inc.

    Subject of the article, reporting Q2 revenue growth, pipeline metrics, and raised fiscal 2026 guidance while flagging margin and working-capital pressures.

  • Huron Consulting Group Inc.

    Peer mentioned for context on revenue growth; no separate news disclosed in the article.

  • FTI Consulting, Inc.

    Peer mentioned for context on revenue growth; no separate news disclosed in the article.

Related articles

$CRAIHighAI 8/10

CRA International (CRAI) Q2 2026 Earnings Call Transcript

CRA International (CRAI) reported Q2 FY2026 revenue of $210.8 million, up 12.8%, and non-GAAP EPS of $2.16, up 14.9%. Non-GAAP EBITDA was $26.8 million. Management raised full-year 2026 revenue guidance to $805-$820 million and reaffirmed EBITDA margin of 12.0%-13.0%. The company repurchased shares and expanded its $400 million credit facility.

$CRAIMedAI 8/10

CRA International, Inc. Q2 2026 Earnings Call Summary

CRA International reported Q2 2026 record quarterly revenue, up 12.8% year over year, with 95% of its portfolio contributing. Full-year 2026 revenue guidance was raised to $805 million to $820 million, with non-GAAP EBITDA margin of 12.0% to 13.0%. The company expanded its $400 million credit facility and returned $31.4 million to shareholders.

$CRAIMed

CRA (NASDAQ:CRAI) Reports Bullish Q2 CY2026

CRA International (NASDAQ:CRAI) reported Q2 CY2026 revenue of $210.8 million, up 12.8% year over year, exceeding Wall Street’s revenue estimate by 6%, according to the company and analysts. Non-GAAP adjusted EPS was $2.16, up from $1.88 a year earlier and 0.6% above consensus. The stock rose 1.9% to $179.96 after results.

$CRAIMed

CHARLES RIVER ASSOCIATES (CRA) REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026

CRA INTERNATIONAL, INC. (CRAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contacts: Eric Nierenberg Nicholas Manganaro Charles River Associates Sharon Merrill Advisors investor@crai.com crai@investorrelations.com 617-425-3020 617-542-5300 CHARLES RIVER ASSOCIATES (CRA) REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 Record Revenue

$GMABHighAI 9/10

Why is Genmab stock surging today?

Genmab's stock rose 6.8% after positive Phase 3 trial results for its ovarian cancer drug, Rina-S, showing improved survival rates. Analysts raised price targets, with Guggenheim setting it at $54. The company's stock hit a 52-week high of $44. Genmab's revenue guidance was also increased, driven by strong sales of DARZALEX.